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Sarcoidosis is a global disorder whose breadth of organ involvement can often be
underappreciated. Head and neck manifestations include involvement of the skin, salivary
glands, sinonasal cavity, and larynx. Of cases of upper airway sarcoidosis, laryngeal
sarcoidosis and airway compromise portend a greater risk of fatal outcomes.
People representing all racial groups have been diagnosed with sarcoidosis. Although many
studies have evaluated incidence and manifestations of sarcoidosis in multiple ethnicities,
few studies have explored racial predilection for laryngeal involvement. However,
assertions that disease severity and poor outcome may be tied to the African diaspora
as well as related socio-economic and cultural realities have been recognized.
We present our case series of six African–American patients diagnosed with sarcoidosis and
presented with complaints of voice change and increased shortness of breath. Four of them
required expeditious, surgical management of the airway. Two had limited supraglottic
involvement and have avoided tracheotomy with aggressive and timely pharmacother-
apeutic intervention and close clinical surveillance. Early recognition of laryngeal
manifestations of sarcoidosis and airway compromise is essential to provide patients with
conservative management without the need for aggressive surgical intervention.
& 2007 Elsevier Ltd. All rights reserved.Introduction
The clinical ubiquity of sarcoid manifestations is widely
appreciated. Upper respiratory tract involvement with
sarcoidosis (SURT) is well recognized, but localized, sympto-
matic supraglottic involvement with sarcoidosis is relativelyElsevier Ltd. All rights reserved.
996 8562;
(H.S. Sims).rare.1 When considering treatment strategies, it seems best
to distinguish between anatomic sites of involvement inclu-
ded in the umbrella of the upper airway. Involvement of the
sinonasal mucosa and septum with consequent dyspnea is a
distinct clinical situation. Additionally, involvement of
salivary glands, skin, and oral mucosa solely do not increase
risk of fatal outcomes. In contrast, supraglottic or glottic
involvement that would produce stridor requires an accel-
erated management paradigm.
Sarcoidosis is reported in essentially all cultures and
continents. However, clinical polymorphism and varied
ARTICLE IN PRESS
H.S. Sims, K.H. Thakkar2280manifestations have been observed. As an example, the
association between cutaneous lesions and systemic invol-
vement has been documented in Nigeria, Turkey, and
numerous European nations.2,3 Darker skinned individuals,
however, have tended to manifest more aggressive cuta-
neous lesions.4,5 A direct correlation between aggressive
cutaneous lesions and a grave prognosis has not been
established. In addition, there are multiple reports that
support a preponderance of sarcoid cases amongst Africa-
n–Americans and Afro-Caribbean people in comparison to
Caucasians.6,7 Additionally, variations in mortality have
been documented with greater mortality in the African-
American population.8,9 A genetic predisposition amongst
people of African descent has been proposed.10 Our current
understanding has been unable to quantify the relative
contributions of genotype and environmental factors though
both apparently play a causative role.
Specific laryngeal infiltration of sarcoid granulomas is
relatively rare. A 31-year review at Mayo clinic identified
2319 patients with sarcoidosis, 220 (9%) of which had head
and neck manifestations.1 Thirteen patients in the popula-
tion had laryngeal involvement, of which eleven had
supraglottic involvement. Other studies have confirmed
the rare involvement of the larynx in sarcoidosis.3,11,12
Symptomotology associated with laryngeal sarcoidosis in-
cludes some combination of voice change, stridor, cough,
dysphagia, or dyspnea.12 The phrase ‘‘turban shaped
epiglottis’’ as pathognomic for supraglottic sarcoid infil-
trate.1 Specifically, the fullness in the rim of the epiglottis
with edematous, pale, diffuse enlargement with areas of
erythema and a granular appearance along supraglottic
structures is consistent with laryngeal sarcoidosis.
We present our series of six African–American patients
diagnosed with sarcoidosis and presented with complaints of
voice change and increased shortness of breath. In four
cases, airway complaints were reported to primary care
providers approximately 6–12 months prior to otolaryngo-
logic evaluation and definitive airway management. One
African–American female had the uncommon presentation
of cutaneous lesions and isolated glottic involvement of the
laryngeal squamous epithelium. An additional patient hadTable 1 Summary of patient data.
Case Gender Age Cutaneous
involvement
Anatomic su
1 Male 50 Scalp Supraglottis
2 Female 50 Nasal rim,
left orbit
Supraglottis
3 Female 48 No Supraglottis
4 Male 43 No Supraglottis
5 Female 50 No Posterior glo
arytenoids
6 Female 50 Lupus pernio Glottis, voc
mucosainvolvement of the arytenoids mucosa without significant
airway obstruction. Both these patients were successfully
managed without a surgical airway. Prompt evaluation of
airway symptoms significantly alters management course.
We compare our findings with laryngeal sarcoidosis with
global literature and address health care disparities in
managing this disorder.Patients
Of the six patients that have presented to our institution for
laryngeal sarcoidosis from 2003 to 2006, four presented in
airway distress requiring urgent care. Two patients pre-
sented to the emergency department (ED) in our institution.
One required an emergent tracheotomy. The other required
an urgent surgical airway within 6 days (the patient refused
emergent tracheotomy initially). The other two patients
presented in a similar fashion to outside institutions and
were referred to us for management. An otolaryngologist,
prior to preoperative examination, had evaluated none of
these patients when tracheotomy was imminent. These four
patients had supraglottic infiltrates that prevented visuali-
zation of the true vocal folds. Two other patients had airway
symptoms, but early referral and evaluation allowed for
aggressive medical and surgical intervention without the
need for a tracheotomy. All patients had been treated for
asthma in the past (Table 1).
Case 1: A 50 year-old African–American male presented to
the ED with bi-phasic stridor with accessory respiratory
muscle use. Because of his known sarcoidosis, he was taking
prednisone 5mg daily at the time of this presentation. He
had no history of cutaneous lesions. Flexible fiberoptic
nasolaryngoscopy (FFL) in the ED revealed bulbous changes
of the epiglottis and edema of the mucosa overlying the
arytenoids mucosa. The false vocal folds were prominent
and the true vocal folds were not visible (Image 1). The
clinical presentation demanded that the airway be secured
surgically. Biopsy confirmed profound supraglottic infiltra-
tion with non-caseating granulomas. He underwent supra-
glottoplasty, excision of obstructive supraglottic tissue,bsite Treatment Outcome
Trach, CO2 laser, oral
steroids
Decannulated stable










ttis, Oral steroids Clinically improving
al fold Steroid injection Relapsing hoarseness
ARTICLE IN PRESS
Airway involvement and obstruction from granulomas in African–American patients with sarcoidosis 2281under microsuspension laryngoscopy with carbon dioxide
(CO2) laser. Specifically, the patient had excision of the right
side of the epiglottis and lysis of both aryepiglottic disease
and folds to enlarge the airway. Additionally, the laryngeal
surface of the epiglottis was partially resected remove
adhesion to the laryngeal inlet. After CO2 laser supraglotto-
plasty, he was successfully decannulated and has been free
of airway complaints for 19 months without pharmacologic
intervention.Image 2 (A) Patient 1: Supraglottic infiltrate with pinhole
airway. (B) Patient 1: Infiltrate on lingual surface of epiglottis.
Image 1 Patient 3: Normal epiglottis and posterior glottis.
There is significant infiltrate in ventricular folds and the
laryngeal ventricles obscuring the true vocal folds.Case 2: A 50 year-old African–American female with a
known history of extra-pulmonary sarcoidosis with ocular
involvement presented to the ED reporting increased
dyspnea and a voice change. There was no history of
cutaneous lesions. FFL demonstrated posterior glottic
edema and interarytenoid inflammation consistent with
reflux. Additionally, there was arytenoid mucosal hypertro-
phy, aryepiglottic fold edema, a bulbous epiglottis and false
vocal fold hypertrophy. The ‘‘turban-shaped’’ epiglottis
raised suspicion about supraglottic sarcoid infiltration.
Videostroboscopy demonstrated progression of infiltrates
and the true vocal folds were not visible (Image 2). The
patient was offered a tracheotomy, but initially refused.
Tracheotomy was performed less than one week after the
initial presentation to the ED due to progressive dyspnea.
Direct laryngoscopy revealed infiltrates in the epiglottis,
and in the supraglottis bilaterally extending from the
aryepiglottic folds to the false cords. The patient underwent
a staged supraglottoplasty due to extent of disease. Primary
surgical invention involved excision of bulky granulomas as
well as lysis of aryepiglottic folds. A second intervention
involved removal of lesions from the false vocal folds and
arytenoids. The patient has been successfully decannulated.
Case 3: A 48 year-old African–American female with a
history of sarcoidosis presented to us for management of
aphonia. She was initially diagnosed with asthma and later
found to have sarcoidosis. Respiratory distress prompted
urgent tracheotomy at an outside institution. She had
maintained a tracheotomy for approximately 1 year prior
to our management. The patient has undergone multiple
supraglottoplasties to remove supraglottic infiltrate that is
encompassing and prevents visualization of the true vocal
folds (Image 3). Secondary to degree of disease and
expected post-surgical scarring after each intervention,
the patient continues to have tracheotomy tube for
ventilation.
Case 4: A 43 year-old African–American male with a
history of sarcoidosis diagnosed approximately 13 years prior
to his respiratory event presented to an outside institution
with airway distress and required an urgent tracheotomy. He
presented to us for a discussion about decannulation
options. Videostroboscopy demonstrated a supraglottic
infiltrates and a marginal airway (Image 2B). A supraglotto-
plasty was attempted, but could not be performed
secondary to lack of exposure of the larynx secondary to
severe cervical spine inflexibility. Steroid injection via
flexible laryngoscope has been partially beneficial, but he
remains tracheostomy dependent.
Case 5: A 49 year-old African–American female with
known sarcoidosis was admitted for dyspnea. Patient
comoridities included morbid obesity, polysubstance abuse,
asthma and viral hepatitis. Otolaryngologic consultation
revealed posterior glottic infiltrate involving the arytenoid
mucosa. Although partially obstructive, the airway could be
visualized and was deemed patent. The patient did not
warrant surgical intervention and was able to be managed
medically for her supraglottic infiltrates with oral steroids
and proton-pump inhibitors.
Case 6: A 50 year-old African–American female with
sarcoidosis and lupus pernio (LP) presented to us with severe
deterioration in her voice affecting her work and social
communicative ability. Videostroboscopy demonstrated that
ARTICLE IN PRESS
Image 3 Patient 2: Staged CO2 Laser removal of infiltrate to
prevent synechiae formation and restore airway.
H.S. Sims, K.H. Thakkar2282the vocal fold mucosa was inflamed. LP involved her left
eyelid and malar region. Direct steroid injection of the vocal
fold and cutaneous lesions improved both subsites.Discussion
We present six cases with varying degrees of supraglottic
airway involvement in sarcoidosis. All patients are Africa-
n–American with diagnosed sarcoidosis prior to developing
airway manifestations. Depending on degree of involve-
ment, management strategy varied greatly. Based on our
study, it appears that a delay in diagnosis of laryngeal
involvement of sarcoidosis portends the need for surgical
airway management.
The possibility of airway involvement with sarcoidosis,
though relatively uncommon, must be considered in patients
with known granulomatous disease. In studies with greater
than 500 patients with sarcoid, presence of laryngeal lesions
is measured between 0.5% and 1%.13 It is difficulty to
ascertain the exact incidence of laryngeal involvement as
most sarcoid patients do not undergo laryngoscopy by a
laryngologist. A great majority of cases have involvement of
the supraglottis, most commonly the epiglottis, followed by
arytenoids, aryepiglottic folds, and false vocal folds.12
Involvement of the true vocal folds and subglottis is rare
in sarcoidosis. When airway symptoms are present, evalua-
tion via laryngoscopy is warranted. In a case review of 44
patients with laryngeal sarcoidosis, symptoms included
hoarseness (59%), dyspnea/stridor (47%), dysphagia (85%),
cough (13%), and absence of laryngeal symptoms (18%).12
Prompt evaluation of these symptoms can prevent need for
tracheotomy as was required in a majority of our case
series.
A laryngoscopy with biopsy under local or general
anesthesia is required for confirmation of sarcoid histo-
pathology. Characteristically, a non-caseating granuloma
consists of clusters of tubercles in the same stage of
development, which are composed on epithelioid cells,
giant cells, and inflammatory infiltrate. Due to degree of
scarring associated with laryngeal sarcoid, adequate speci-
men is required to confirm diagnosis. In our review, four of
the six patients had biopsy proven non-caseating granulomas
recovered from the supraglottis. One patient could notextend his neck and a direct laryngoscope could not be
placed, hence biopsy through a flexible laryngoscope
confirmed sarcoid granulomas.
Management strategy is dependent on the degree of
involvement of the airway. No therapy is required for
sarcoidosis of the larynx if the patient is asymptomatic, but
close follow-up is warranted to evaluate disease progres-
sion.14 Systemic corticosteroid therapy is the treatment in
most cases. Intralesional steroid injections for focal disease
can be beneficial in select individuals.1,12 The carbon
dioxide laser can be used to remove lesions causing airway
obstruction, it is preferable to address sarcoid lesions while
they are non-obstructive and possibly avoid the need for a
tracheotomy.15,16 The need for tracheotomy in laryngeal
sarcoid is indicated in cases of imminent airway obstruction
and progression of disease despite medical therapy. Neel
et al. in his review reported 6 of 13 patients requiring
tracheotomy.1 Our case review demonstrates 4 of 6
individuals with tracheotomy secondary to severity of
disease pathology. After analysis, the majority of our
patients had complained of stridor for more than six months
and the airway symptoms were progressive. Initial steroid
therapy in the ED failed to provide sustained relief for any of
these patients. Two patients were referred for otolaryngo-
logic management at the time of initial airway symptoms
have been successfully managed without a surgical airway.
Overall, the intrapulmonary manifestations appear to be
better understood, but endoscopic evaluation of the larynx
is recommended in a patient who has sarcoidosis and begins
to manifest airway symptoms.
Skin lesions occur in approximately a quarter of patients
with sarcoidosis and are classified into specific and non-
specific for sarcoidosis.17 Where as the most prevalent non-
specific lesion of sarcoidosis is erythema nodosum, the most
specific lesion is lupus pernio.18 There have been associa-
tions between LP and extrapulmonary sarcoid, specifically
SURT. LP is a chronic, firm, raised, violaceous lesion of the
skin which can involve the nose, ears, elbow, hands, fingers,
perioral, and eyelids.18 The presence of LP in sarcoidosis is
reported between 2.7% and 4.2% percent.19–21 The associa-
tion of LP and SURT has been documented as high as 54% in
one study of 818 patients.11 Multiple authors have at-
tempted to link lupus pernio with involvement of the larynx.
Jacyk reported on 45 black South Africans and stated there
was a relatively low predictive value of LP with only 3 of 45
patients displaying cutaneous lesions and laryngeal involve-
ment.5 Neville reported on the relationship between LP and
SURT specifically. All the patients showed an association
between SURT and LP. However, when the larynx was
considered separately, less than one-third of the patients
had LP in association with glottic airway involvement.22 With
regards to our study, only 16% of patients had LP and glottic
sarcoidosis. Analysis of specific subsite involvement seems
to reduce the predictive value of cutaneous lesions for
laryngeal involvement.
It remains unclear why a disproportionate number of
African–Americans experience mortality from the disease
although it may be a result of greater incidence of this
disease in the African–American population.8,10 The mortal-
ity rate for sarcoidosis among African–Americans has been
reported drastically higher that of Caucasian Americans.6,8,9
Race has even been implicated in poorer outcomes after
ARTICLE IN PRESS
Airway involvement and obstruction from granulomas in African–American patients with sarcoidosis 2283lung transplantation for pulmonary involvement of sarcoi-
dosis.23 The relative contributions of genetic predisposition
versus environmental disparities towards the development
of advanced laryngeal involvement in our patient population
remains unclear. However, it seems reasonable for clinicians
to maintain a high index of suspicion for airway involvement
in any patient with sarcoidosis. This vigilance may be
particularly important for African–American patients. Fu-
ture research might include population studies to determine
statistical significance of ethnic variability and laryngeal
sarcoidosis.
Early assessment of airway symptoms in patients with
sarcoidosis may allow for conservative management and
avoidance of aggressive surgical management. Cutaneous
manifestation of sarcoidosis may have an association with
SURT, but have decreased consistency for predicting
laryngeal involvement. Our findings concur with higher
reported morbidity amongst African–Americans and routine
surveillance may prevent disease sequelae. Involvement of
an otolaryngologist in patient care may allow for greater
detection of laryngeal lesions of sarcoidosis.
Conflict of interst
For both authors, Dr. H. Steven Sims and Dr. Kunal H. Thakkar,
there are no financial conflicts of interest (employment,
consultancy, stock ownership, honoraria and paid expert
testimony) as well as other forms of conflict of interest,
including personal, academic and intellectual issues.
Acknowledgment
We would like to thank Shamila G. Rawal, MD, for her
assistance with manuscript revision.
References
1. Neel III. HB, McDonald TJ. Laryngeal sarcoidosis: report of 13
patients. Ann Otol Rhinol Laryngol 1982;91:359.
2. Awotedu AA, George AO, Oluboyo PO, et al. Sarcoidosis in
Africans: 12 cases with histological confirmation from Nigeria.
Trans R Soc Trop Med Hyg 1987;81:1027.
3. Yanardag H, Enoz M, Papila I, et al. Upper respiratory tract
involvement of sarcoidosis in the Turkish population. Otolar-
yngol Head Neck Surg 2006;134:848.4. Mosam A, Morar N. Recalcitrant cutaneous sarcoidosis: an
evidence-based sequential approach. J Dermatolog Treat
2004;15:353.
5. Jacyk WK. Cutaneous sarcoidosis in black South Africans. Int J
Dermatol 1999;38:841.
6. Rybicki BA, Major M, Popovich Jr. J, et al. Racial differences in
sarcoidosis incidence: a 5-year study in a health maintenance
organization. Am J Epidemiol 1997;145:234.
7. Israel HL. Influence of race and geographical origin on
sarcoidosis. Arch Environ Health 1970;20:608.
8. Gideon NM, Mannino DM. Sarcoidosis mortality in the United
States 1979–1991: an analysis of multiple-cause mortality data.
Am J Med 1996;100:423.
9. James DG. Epidemiology of sarcoidosis. Sarcoidosis 1992;
9:79.
10. Luisetti M, Beretta A, Casali L. Genetic aspects in sarcoidosis.
Eur Respir J 2000;16:768.
11. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for
chronic sarcoidosis. Chest 2002;122:227.
12. Bower JS, Belen JE, Weg JG, Dantzker DR. Manifestations and
treatment of laryngeal sarcoidosis. Am Rev Respir Dis 1980;
122:325.
13. Gallivan GJ, Landis JN. Sarcoidosis of the larynx: preserving and
restoring airway and professional voice. J Voice 1993;7:81.
14. Dean CM, Sataloff RT, Hawkshaw MJ, Pribikin E. Laryngeal
sarcoidosis. J Voice 2002;16:283.
15. Ruff T, Bellens EE. Sarcoidosis of the larynx treated with CO2
laser. J Otolaryngol 1985;14:245.
16. Davis RK, Shapshay SM, Strong MS, Hyams VJ. Transoral partial
supraglottic resection using the CO2 laser. Laryngoscope
1983;93:429.
17. Hubert A, Watteeuw G, Tannouri F, et al. Systemic sarcoidosis
with cutaneous lesions: literature review. Acta Clin Belg
1995;50:207.
18. Mana J, Marcoval J, Graells J, et al. Cutaneous involvement in
sarcoidosis. Relationship to systemic disease. Arch Dermatol
1997;133:882.
19. Yanardag H, Pamuk ON, Pamuk GE. Lupus pernio in Sarcoidosis:
clinical features and treatment outcomes of 14 patients. J Clin
Rheumatol 2003;9:72.
20. Spiteri MA, Matthey F, Gordon T, et al. Lupus pernio: a clinico-
radiological study of thirty-five cases. Br J Dermatol 1985;
112:315.
21. James DG. Lupus pernio. Lupus 1992;1:129.
22. Neville E, Mills RG, James DG. Sarcoidosis of the upper
respiratory tract and its relation to lupus pernio. Ann NY Acad
Sci 1976;278:416.
23. Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race,
and short-term outcomes following lung transplantation. Chest
2004;125:990.
